The article you requested is
Aripiprazole Treatment of Risperidone-Induced Hyperprolactinemia
Jing Xu Chen, Yun Ai Su, Shao Li Wang, Qing Tao Bian, Yan Hong Liu, Ning Wang, Fu De Yang, Colin Haile, Thomas R. Kosten, and Xiang Yang Zhang
J Clin Psychiatry 2009;70(7):1058-1059 [letter]
10.4088/JCP.08l04671
© Copyright 2015 Physicians Postgraduate Press, Inc.
To view this item, select one of the options below.
-
-
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
-
Subscribe
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
-
-
Activate
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
-
Sign in
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
-
Click here to login.
-
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Article Abstract
Letter to the Editor
Sir: Hyperprolactinemia is a well-recognized complication
of some antipsychotic agents that results from the blocking of
dopamine-2 (D2) receptors in the anterior pituitary. Aripiprazole,
a potent partial agonist of the D2 receptors, inhibits spontaneous
prolactin release from isolated anterior pituitary slices. Clinically,
switching to aripiprazole monotherapy resolves antipsychoticinduced
hyperprolactinemia.